SCHEDULE: Glazer Capital Exits IGM Biosciences Stake

Glazer Capital, LLC and Paul J. Glazer report a complete divestment of their beneficial ownership in IGM Biosciences, Inc. as of September 30, 2025.

Summary

• Glazer Capital, LLC and Paul J. Glazer, collectively referred to as the Reporting Persons, have filed an Amendment No. 1 to Schedule 13G for IGM Biosciences, Inc.
• The filing indicates that as of September 30, 2025, the Reporting Persons beneficially own 0.00 shares of IGM Biosciences, Inc. Common Stock, representing 0.00% of the class.
• Glazer Capital, LLC serves as the investment manager for certain funds and managed accounts (Glazer Funds), while Mr. Paul J. Glazer is the Managing Member of Glazer Capital.
• The address for the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: The complete divestment of shares by an institutional investor is generally perceived as a negative signal, indicating a lack of confidence or a strategic exit from the investment.

Negatives

• Glazer Capital, LLC and Paul J. Glazer have reduced their beneficial ownership in IGM Biosciences, Inc. to 0.00%, indicating a complete divestment of their stake.

Risks

• The complete divestment by an institutional investor like Glazer Capital could signal a lack of confidence in IGM Biosciences' future prospects or a shift in investment strategy by the reporting persons.
• Such a significant reduction in institutional ownership may lead to negative market perception and potential downward pressure on the stock price.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding IGM Biosciences, Inc.'s operational or financial performance, focusing solely on the reporting persons' beneficial ownership.

Industry Context

This filing primarily concerns a change in institutional ownership and does not offer insights into broader industry trends or competitive landscape for IGM Biosciences, Inc.

Stakeholder Impact

• Shareholders may view the complete divestment by Glazer Capital as a negative indicator, potentially leading to decreased investor confidence and selling pressure on IGM Biosciences' stock.

Key Dates

Recommendation

The complete divestment by an institutional investor like Glazer Capital, LLC, reducing their stake to 0%, is a strong negative signal. This action suggests a lack of conviction in the company's future performance or a strategic decision to exit the position entirely. For a seasoned investor, this would typically warrant a 'sell' recommendation, especially if they hold the stock, to avoid potential future downside or to reallocate capital to more promising opportunities.

Keywords

IGM Biosciences, Glazer Capital, Paul J. Glazer, Schedule 13G, Beneficial Ownership, Divestment, Institutional Investor, Common Stock, SEC Filing